TOC - Global PD-1 PDL-1 Inhibitor Market.pdf

1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
res
Focus on Epidemiology, Product, and
Region
Analysis and Forecast: 2022-2032
August 2022
PD-1/PDL-1
Inhibitor Market
- A Global and
Regional Analysis
Table of Content

2
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
Table of Content
Executive Summary ........................................................................ 24
1. Market Definition ...................................................................... 27
1.1 Inclusion and Exclusion Criteria ....................................................................27
2. Research Scope....................................................................... 28
2.1 Target audience ...............................................................................................29
2.2 Key questions answered in the report...........................................................29
3. Research Methodology............................................................. 31
3.1 Global PD-1/PDL-1 Inhibitor Market: Research Methodology......................31
3.2 Primary Data Sources .....................................................................................32
3.3 Secondary Data Sources ................................................................................32
3.4 Target Patient Pool Estimation Model ...........................................................33
3.5 Criteria for Company Profiling........................................................................34
4. Markets.................................................................................... 35
4.1 Market Overview ..............................................................................................36
4.2 PD-1/PDL-1 Inhibitors: Overview....................................................................36
4.2.1 PD-1/PDL-1 Inhibitors and their role in Cancer immunotherapy.............36
4.2.2 Historic Development of PD-1/PDL-1 Inhibitors........................................36
4.2.3 Mechanism of Action of PD-1/PDL-1 Inhibitors ........................................37
4.2.4 Market Landscape .......................................................................................39
4.2.4.1 Approved PD-1/PDL-1 Inhibitors ......................................................................39
4.2.4.2 Competitive Landscape....................................................................................47
4.2.4.2.1 Strategic Activities.................................................................................................... 47
4.2.4.2.2 Regional Distribution of Companies......................................................................... 48
4.2.5 Market Dynamics.........................................................................................52
4.2.5.1 Market Drivers..................................................................................................52
4.2.5.1.1 Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer
Indications ............................................................................................................... 52
4.2.5.1.2 Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens ........................... 53
4.2.5.2 Market Restraints.............................................................................................55

4
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
4.2.5.2.1 Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor
Treatment are a Cause of Concern......................................................................... 55
4.2.5.2.2 Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption
of PD-1/PDL-1 Inhibitor Treatment.......................................................................... 56
4.2.5.3 Opportunities....................................................................................................56
4.2.5.3.1 Promising Therapeutic Outcomes Generating Positive Market Sentiments............ 56
4.2.5.3.2 Demand for Safer and Convenient Formulation ...................................................... 56
5. Indications ............................................................................... 57
5.1 Indications........................................................................................................58
5.1.1 Non-Small Cell Lung Cancer (NSCLC).......................................................58
5.1.1.1 Non-Small Cell Lung Cancer (NSCLC): Disease Overview ..............................58
5.1.1.2 Non-Small Cell Lung Cancer (NSCLC): Disease Pathophysiology ...................58
5.1.1.3 Non-Small Cell Lung Cancer (NSCLC): Treatment...........................................59
5.1.2 Melanoma.....................................................................................................61
5.1.2.1 Melanoma: Disease Overview..........................................................................61
5.1.2.2 Melanoma: Disease Pathophysiology...............................................................61
5.1.2.3 Melanoma: Treatment ......................................................................................62
5.1.3 Hepatocellular Carcinoma (HCC) ...............................................................65
5.1.3.1 Hepatocellular Carcinoma (HCC): Disease Overview.......................................65
5.1.3.2 Hepatocellular Carcinoma (HCC): Disease Pathophysiology............................65
5.1.3.3 Hepatocellular Carcinoma (HCC): Treatment ...................................................66
5.1.4 Colorectal Cancer (CRC).............................................................................69
5.1.4.1 Colorectal Cancer (CRC): Disease Overview ...................................................69
5.1.4.2 Colorectal Cancer (CRC): Disease Pathophysiology........................................70
5.1.4.3 Colorectal Cancer (CRC): Treatment ...............................................................71
5.1.5 Breast Cancer ..............................................................................................74
5.1.5.1 Breast Cancer: Disease Overview....................................................................74
5.1.5.2 Breast Cancer: Pathophysiology ......................................................................74
5.1.5.3 Breast Cancer: Treatment ................................................................................75
5.1.6 Urothelial Carcinoma ..................................................................................77

5
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
5.1.6.1 Urothelial Carcinoma: Disease Overview .........................................................77
5.1.6.2 Urothelial Carcinoma: Pathophysiology............................................................78
5.1.6.3 Urothelial Carcinoma: Treatment......................................................................78
6. Products .................................................................................. 82
6.1 Global PD-1/PDL-1 Inhibitor Pipeline Analysis (by Phase) ..........................83
6.1.1 By Development Phase...............................................................................83
6.1.2 By Drug Class..............................................................................................83
6.1.3 By Route of Administration (RoA) .............................................................84
6.1.4 By Monotherapy/Combination Therapy Type ...........................................85
6.1.5 By Target......................................................................................................98
7. Region ..................................................................................... 99
7.1 North America................................................................................................101
7.1.1 Melanoma...................................................................................................102
7.1.1.1 Melanoma: Epidemiology ...............................................................................102
7.1.2 Breast Cancer ............................................................................................103
7.1.2.1 Breast Cancer: Epidemiology.........................................................................103
7.1.3 Colorectal Cancer (CRC)...........................................................................104
7.1.3.1 Colorectal Cancer (CRC): Epidemiology ........................................................104
7.1.4 Non-Small Cell Lung Cancer (NSCLC).....................................................105
7.1.4.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology....................................105
7.1.5 Hepatocellular Carcinoma (HCC) .............................................................106
7.1.5.1 Hepatocellular Carcinoma (HCC): Epidemiology............................................106
7.1.6 Urothelial Carcinoma ................................................................................107
7.1.6.1 Urothelial Carcinoma: Epidemiology...............................................................107
7.2 U.K. .................................................................................................................109
7.2.2 Melanoma...................................................................................................111

6
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
7.2.5 Breast Cancer ............................................................................................114
7.3 Germany .........................................................................................................116
7.3.2 Melanoma...................................................................................................118
7.3.5 Breast Cancer ............................................................................................121
7.4 France.............................................................................................................123
7.4.2 Melanoma...................................................................................................125
7.4.5 Breast Cancer ............................................................................................128

7
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
7.5 Italy .................................................................................................................130
7.5.2 Melanoma...................................................................................................132
7.5.5 Breast Cancer ............................................................................................135
7.6 Spain...............................................................................................................137
7.6.2 Melanoma...................................................................................................139
7.6.5 Breast Cancer ............................................................................................142
7.7 Japan ..............................................................................................................145

8
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
7.7.2 Melanoma...................................................................................................147
7.7.5 Breast Cancer ............................................................................................150
8. Markets - Competitive Benchmarking & Company Profiles....... 152
8.1 GlaxoSmithKline plc......................................................................................153
8.1.1 Company Overview ...................................................................................153
8.1.2 Role of GlaxoSmithKline plc in Global PD-1/PDL-1 Inhibitor Market....153
8.1.3 Product Portfolio .......................................................................................154
8.1.4 Key Competitors of the Company............................................................154
8.1.5 Financials...................................................................................................155
8.1.6 Key Insights About Financial Health of the Company ...........................157
8.1.7 Business Strategies ..................................................................................157
8.1.7.1 Product Developments...................................................................................157
8.1.8 Corporate Strategies.................................................................................158
8.1.8.1 Partnership and Collaboration........................................................................158
8.1.9 Analyst’s Perspective ...............................................................................159
8.2 Bristol-Myers Squibb Company ...................................................................160
8.2.2 Role of Bristol-Myers Squibb Company in Global PD-1/PDL-1
Inhibitor Market..........................................................................................160

9
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
8.2.5 Financials...................................................................................................162
8.2.8.1 Merger and Acquisitions.................................................................................168
8.3 Arcus Biosciences, Inc..................................................................................171
8.3.2 Role of Arcus Biosciences, Inc. in Global PD 1/PDL-1 inhibitor
Market.........................................................................................................171
8.3.5 Financials...................................................................................................173
8.3.8.1 Partnerships and Collaboration ......................................................................175
8.4 Agenus Inc. ....................................................................................................177
8.4.2 Role of Agenus Inc. in Global PD 1/PDL-1 Inhibitor Market...................177
8.4.4 Financials...................................................................................................178

10
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
8.4.7.1 Partnerships and Collaboration ......................................................................181
8.5 F. Hoffmann-La Roche Ltd............................................................................183
8.5.2 Role of F. Hoffmann-La Roche Ltd in Global PD 1/PDL-1 inhibitor
Market.........................................................................................................183
8.5.5 Financials...................................................................................................185
8.6 Astra Zeneca PLC..........................................................................................191
8.6.2 Role of Astra Zeneca PLC in Global PD 1/PDL-1 inhibitor Market ........191
8.6.5 Financials...................................................................................................193
8.6.9 Analyst’s Insight........................................................................................196
8.7 Beigene Ltd. ...................................................................................................197
8.7.2 Role of Beigene Ltd. in Global PD 1/PDL-1 inhibitor Market..................197

11
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
8.7.5 Financials...................................................................................................199
8.8 Shanghai Junshi Bioscience Co. Ltd...........................................................206
8.8.2 Role of Shanghai Junshi Bioscience Co., Ltd. in Global PD 1/PDL-1
inhibitor Market..........................................................................................206
8.8.5 Financials...................................................................................................208
8.9 Shanghai Henlius Biotech, Inc. ....................................................................213
8.9.2 Role of Shanghai Henlius Biotech, Inc. in Global PD 1/PDL-1
inhibitor Market..........................................................................................213
8.9.5 Financials...................................................................................................215

12
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
8.10 Jiangsu HengRui Medicine Co., Ltd.............................................................220
8.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in Global PD 1/PDL-1
Inhibitor Market..........................................................................................220
8.10.5 Financials...................................................................................................222
8.11 Lee's Pharmaceutical Limited.......................................................................225
8.11.2 Role of Lee's Pharmaceutical Limited in Global PD 1/PDL-1 inhibitor
Market.........................................................................................................225
8.11.5 Financials...................................................................................................227
8.12 Incyte Corporation.........................................................................................229

13
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
8.12.2 Role of Incyte Corporation in Global PD-1/PDL-1 inhibitors Market.....229
8.12.5 Financials...................................................................................................231
8.12.8.1 Collaboration and Agreement.........................................................................233
8.13 Biocad.............................................................................................................234
8.13.2 Role of Biocad in Global PD-1/PDL-1 Inhibitors Market.........................234
8.14 CStone Pharmaceuticals...............................................................................237
8.14.2 Role of CStone Pharmaceuticals in Global PD-1/PDL-1 Inhibitors
Market.........................................................................................................237
8.14.5 Financials...................................................................................................239

14
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
9. BIS Research Recommendations............................................ 243
9.1 Current Market Scenario ...............................................................................243
9.2 Future Scenario .............................................................................................243
9.3 Key Success Factors and Challenges .........................................................243
9.3.1 Success Factors........................................................................................243
9.3.2 Key Challenges..........................................................................................244

15
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
List of Figures
Figure 1: PD-1/PDL-1 Inhibitor Market Share (by Sales), $Million, 2021
Figure 2: Number of Eligible Patients Specific to Indication for 2022
Figure 3: Global PD-1/PDL-1 Inhibitor Market Segmentation
Figure 4: Global PD-1/PDL-1 Inhibitor Market Methodology
Figure 5: Primary Research Methodology
Figure 6: Historic Development of PD-1/PDL-1 Inhibitors
Figure 7: Role of PD-1/PDL-1 in Tumor Protection
Figure 8: Key Market Players (by Sales), $Million, 2021
Figure 9: Number of Strategic Activities
Figure 10: Regional Distribution of Companies
Figure 11: Non-Small Cell Lung Cancer (NSCLC) Disease Pathophysiology
Figure 12: Melanoma Disease Pathophysiology
Figure 13: Melanoma: Treatment Options
Figure 14: Hepatocellular Carcinoma (HCC): Disease Pathophysiology
Figure 15: Hepatocellular Carcinoma (HCC) Treatment
Figure 16: Hepatocellular Carcinoma (HCC) Treatment Algorithm
Figure 17: Chromosomal Instability (CIN) Pathway and Microsatellite Instability (MSI) Pathway
Figure 18: Serrated Pathway
Figure 19: Colorectal Cancer (CRC): Treatment Algorithm
Figure 20: Breast Cancer: Disease Pathophysiology
Figure 21: Breast Cancer: Treatment
Figure 22: Urothelial Carcinoma: Disease Pathophysiology
Figure 23: Urothelial Carcinoma Treatment Types
Figure 24: Urothelial Carcinoma Treatment Algorithm
Figure 25: Number of PD-1/PDL-1 Inhibitor Clinical Trials
Figure 26: Number of Clinical Trials by Drug Class
Figure 27: PD-1/PDL-1 Inhibitor by Therapy (Monotherapy/Combination) Type
Figure 28: PD-1/PDL-1 Inhibitors with Added Entity
Figure 29: U.S. Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 30: U.S. Eligible Patient Population for Melanoma, 2022-2032
Figure 31: U.S. Eligible Patient Population for Breast Cancer, 2022-2032

16
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
Figure 32: U.S. Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 33: U.S. Eligible Patient Population for NSCLC, 2022-2032
Figure 34: U.S. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 35: U.S. Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 36: U.K. Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 37: U.K. Eligible Patient Population for NSCLC, 2022-2032
Figure 38: U.K. Eligible Patient Population for Melanoma, 2022-2032
Figure 39: U.K. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 40: U.K. Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 41: U.K. Eligible Patient Population for Breast Cancer, 2022-2032
Figure 42: U.K. Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 43: Germany Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 44: Germany: Eligible Patient Population for NSCLC, 2022-2032
Figure 45: Germany: Eligible Patient Population for Melanoma, 2022-2032
Figure 46: Germany: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 47: Germany: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 48: Germany: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 49: Germany: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 50: France Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 51: France: Eligible Patient Population for NSCLC, 2022-2032
Figure 52: France: Eligible Patient Population for Melanoma, 2022-2032
Figure 53: France: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 54: France: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 55: France: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 56: France: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 57: Italy Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 58: Italy: Eligible Patient Population for NSCLC, 2022-2032
Figure 59: Italy: Eligible Patient Population for Melanoma, 2022-2032
Figure 60: Italy: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 61: Italy: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 62: Italy: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 63: Italy: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 64: Spain Eligible Population for PD-1/PDL-1 Inhibitor Treatment

17
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
Figure 65: Spain: Eligible Patient Population for NSCLC, 2022-2032
Figure 66: Spain: Eligible Patient Population for Melanoma, 2022-2032
Figure 67: Spain: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 68: Spain: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 69: Spain: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 70: Spain: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 71: Japan Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 72: Japan: Eligible Patient Population for NSCLC, 2022-2032
Figure 73: Japan: Eligible Patient Population for Melanoma, 2022-2032
Figure 74: Japan: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 75: Japan: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 76: Japan: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 77: Japan: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 78: GlaxoSmithKline plc: Product Portfolio
Figure 79: GlaxoSmithKline plc: Overall Financials, $Million, 2019-2021
Figure 80: GlaxoSmithKline plc: Net Revenue (by Segment), $Million, 2019-2021
Figure 81: GlaxoSmithKline plc: Net Revenue (by Region), $Million, 2019-2021
Figure 82: GlaxoSmithKline plc: R&D Expenditure, $Million, 2019-2021
Figure 83: Bristol-Myers Squibb Company: Product Portfolio
Figure 84: Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021
Figure 85: Bristol-Myers Squibb Company: Net Revenue (by Region), $Million, 2019-2021
Figure 86: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021
Figure 87: Arcus Biosciences, Inc.: Product Portfolio
Figure 88: Arcus Biosciences, Inc.: Overall Financials, $Million, 2019-2021
Figure 89: Arcus Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 90: Agenus Inc.: Product Portfolio
Figure 91: Agenus Inc.: Overall Financials, $Million, 2019-2021
Figure 92: Agenus Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 93: Agenus Inc.: R&D Expenditure, $Million, 2019-2021
Figure 94: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 95: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 96: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
Figure 97: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021

18
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
Figure 98: Astra Zeneca PLC: Product Portfolio
Figure 99: Astra Zeneca PLC: Overall Financials, $Million, 2019-2021
Figure 100: Astra Zeneca PLC: Net Revenue (by Region), $Million, 2019-2021
Figure 101: Astra Zeneca PLC: R&D Expenditure, $Million, 2019-2021
Figure 102: Beigene Ltd.: Product Portfolio
Figure 103: Beigene Ltd.: Overall Financials, $Million, 2019-2021
Figure 104: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 105: Shanghai Junshi Bioscience Co., Ltd.: Product Portfolio
Figure 106: Shanghai Junshi Bioscience Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 107: Shanghai Junshi Bioscience Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 108: Shanghai Henlius Biotech, Inc.: Product Portfolio
Figure 109: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021
Figure 110: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 111: Jiangsu HengRui Medicine Co., Ltd.: Product Portfolio
Figure 112: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 113: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 114: Lee's Pharmaceutical Limited: Product Portfolio
Figure 115: Lee's Pharmaceutical Limited: Overall Financials, $Million, 2019-2021
Figure 116: Lee's Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021
Figure 117: Incyte Corporation: Product Portfolio
Figure 118: Incyte Corporation: Overall Financials, $Million, 2019-2021
Figure 119: Incyte Corporation R&D Expenditure, $Million, 2019-2021
Figure 120: Biocad: Product Portfolio
Figure 121: CStone Pharmaceuticals: Product Portfolio
Figure 122: CStone Pharmaceuticals: Overall Financials, $Million, 2019-2021
Figure 123: CStone Pharmaceuticals: Revenue (by Region), $Million, 2019-2021
Figure 124: CStone Pharmaceuticals: R&D Expenditure, $Million, 2019-2021

19
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
List of Tables
Table 1: Approved PD-1/PDL-1 Inhibitors
Table 2: Snapshot: Approved PD-1/PDL-1 Inhibitors
Table 3: Companies by Region
Table 4: Number of Indication Added Since Launch
Table 5: Combination Regimen with PD-1/PDL-1 Inhibitors
Table 6: Non-Small Cell Lung Cancer (NSCLC): Stage Specific Treatment Options
Table 7: Stage-Wise Colorectal Cancer (CRC) Treatment
Table 8: Systemic Therapy for Distant Recurrence Cases of Colorectal Cancer (CRC)
Table 9: PD-1/PDL-1 Inhibitor by Route of Administration (RoA)
Table 10: Combination Regimes by Development Stage
Table 11: Leading PD-1/PDL-1 Inhibitors and Indications in Combination Therapy
Table 12: Leading PD-1/PDL-1 Inhibitors as Monotherapy and Target Indication
Table 13: U.S. Incidence for Cancer Indications, 2022-2032
Table 14: U.S. Prevalence for Cancer Indications, 2022-2032
Table 15: U.K. Incidence for Cancer Indications, 2022-2032
Table 16: U.K. Prevalence for Cancer Indications, 2022-2032
Table 17: Germany Incidence for Cancer Indications, 2022-2032
Table 18: Germany Prevalence for Cancer Indications, 2022-2032
Table 19: France Incidence for Cancer Indications, 2022-2032
Table 20: France Prevalence for Cancer Indications, 2022-2032
Table 21: Italy Incidence for Cancer Indications, 2022-2032
Table 22: Italy Prevalence for Cancer Indications, 2022-2032
Table 23: Spain Incidence for Cancer Indications, 2022-2032
Table 24: Spain Prevalence for Cancer Indications, 2022-2032
Table 25: Japan Incidence for Cancer Indications, 2022-2032
Table 26: Japan Prevalence for Cancer Indications, 2022-2032
Table 27: GlaxoSmithKline plc: Key Competitors
Table 28: Product Development
Table 29: Partnership and Collaboration
Table 30: Potential Registrational Study Readouts Anticipated Through 2023/2024
Table 31: Bristol-Myers Squibb Company: Key Competitors

20
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
Table 32: Product Developments
Table 33: Merger and Acquisitions
Table 34: Arcus Biosciences, Inc.: Key Competitors
Table 36: Partnerships and Collaboration
Table 38: Partnerships and Collaboration
Table 39: F. Hoffmann-La Roche Ltd: Key Competitors
Table 42: Astra Zeneca PLC: Key Competitors
Table 45: Beigene Ltd.: Key Competitors
Table 48: Shanghai Junshi Bioscience Co., Ltd.: Key Competitors
Table 51: Shanghai Henlius Biotech, Inc.: Key Competitors
Table 54: Jiangsu HengRui Medicine Co., Ltd.: Key Competitors
Table 57: Lee's Pharmaceutical Limited: Key Competitors
Table 60: Collaboration and Agreement

21
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

22
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

23
G
L
O
B
A
L
P
D
-
1
/
P
D
L
-
1
I
N
H
I
B
I
T
O
R
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

TOC - Global PD-1 PDL-1 Inhibitor Market.pdf

Recommended

Recommended

More Related Content

More from BIS Research Inc.

More from BIS Research Inc. (20)

TOC - Global PD-1 PDL-1 Inhibitor Market.pdf